Assessment of small fiber neuropathy and distal sensory neuropathy in female patients with fibromyalgia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated sudomotor dysfunction, small fiber neuropathy (SFN), and their clinical significance in female fibromyalgia patients. Methods: Fibromyalgia patients and healthy controls (HCs) were recruited. Clinical and laboratory data were measured. Electrochemical skin conductance (ESC) values of hands and feet were assessed by SUDOSCAN. Additionally, several other methods were employed, including nerve conduction study (NCS), electromyography (EMG), and questionnaires. Spearman correlation coefficient was calculated to identify factors associated with ESC values of SUDOSCAN. Results: Twenty-two female fibromyalgia patients and 22 female HCs were recruited. The fibromyalgia group had lower EQ5D and higher Toronto Clinical Neuropathy scores than the HC group. Most of the EMG/NCS findings of motor and proximal sensory nerves were comparable between the fibromyalgia and HC groups, whereas sensory nerve action potential amplitudes of distal sensory nerves were significantly lower in the fibromyalgia group. Mean ESC values of hands and feet were significantly lower in the fibromyalgia group than in the HC group (57.6 ± 16.2 vs. 68.8 ± 10.3 μS, p = 0.010 for hands, 64.9 ± 11.5 vs. 72.0 ± 8.2 μS, p = 0.025 for feet, respectively). Moderate to severe SFN was more common in the fibromyalgia group (68.2%) than in the HC group (68.2 vs. 50%, p = 0.019). Fibromyalgia disease duration was significantly correlated with the ESC values of hands/feet, and tricyclic antidepressant (TCA) responders had higher ESC values than non-responders. Conclusions: SFN was commonly detected in fibromyalgia patients who had normal EMG/NCS findings and was more severe in fibromyalgia patients with longer disease duration. SUDOSCAN may predict response to TCA therapy.
Abstract
Background/Aims: We investigated sudomotor dysfunction, small fiber neuropathy (SFN), and their clinical significance in female fibromyalgia patients. Methods: Fibromyalgia patients and healthy controls (HCs) were recruited. Clinical and laboratory data were measured. Electrochemical skin conductance (ESC) values of hands and feet were assessed by SUDOSCAN. Additionally, several other methods were employed, including nerve conduction study (NCS), electromyography (EMG), and questionnaires. Spearman correlation coefficient was calculated to identify factors associated with ESC values of SUDOSCAN. Results: Twenty-two female fibromyalgia patients and 22 female HCs were recruited. The fibromyalgia group had lower EQ5D and higher Toronto Clinical Neuropathy scores than the HC group. Most of the EMG/NCS findings of motor and proximal sensory nerves were comparable between the fibromyalgia and HC groups, whereas sensory nerve action potential amplitudes of distal sensory nerves were significantly lower in the fibromyalgia group. Mean ESC values of hands and feet were significantly lower in the fibromyalgia group than in the HC group (57.6 ± 16.2 vs. 68.8 ± 10.3 μS, p = 0.010 for hands, 64.9 ± 11.5 vs. 72.0 ± 8.2 μS, p = 0.025 for feet, respectively). Moderate to severe SFN was more common in the fibromyalgia group (68.2%) than in the HC group (68.2 vs. 50%, p = 0.019). Fibromyalgia disease duration was significantly correlated with the ESC values of hands/feet, and tricyclic antidepressant (TCA) responders had higher ESC values than non-responders. Conclusions: SFN was commonly detected in fibromyalgia patients who had normal EMG/NCS findings and was more severe in fibromyalgia patients with longer disease duration. SUDOSCAN may predict response to TCA therapy.
참고문헌 (40)
- Wolfe F, "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee", Arthritis Rheum, 33, pp.160~172 (1990)
- Wolfe F, "The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity", Arthritis Care Res(Hoboken), 62, pp.600~610 (2010)
- Macfarlane GJ, "EULAR revised recommendations for the management of fibromyalgia", Ann Rheum Dis, 76, pp.318~328 (2017)
- Lauche R, "Patient-related predictors of treatment satisfaction of patients with fibromyalgia syndrome : results of a cross-sectional survey", Clin Exp Rheumatol, 31(6 Suppl 79), pp.S34~S40 (2013)
- Raja SN, "The revised International Association for the Study of Pain definition of pain : concepts, challenges, and compromises", Pain, 161, pp.1976~1982 (2020)
- Pickering G, "Electrochemical skin conductance and quantitative sensory testing on fibromyalgia", Pain Pract, 20, pp.348~356 (2020)
- Viceconti A, "Neuropathic pain and symptoms of potential small-fiber neuropathy in fibromyalgic patients : a national on-line survey", Joint Bone Spine, 88, pp.105153~ (2021)
- Üçeyler N, "Small fibre pathology in patients with fibromyalgia syndrome", Brain, 136(Pt 6), pp.1857~1867 (2013)
- Chae CS, "Rapid, objective and non-invasive diagnosis of sudomotor dysfunction in patients with lower extremity dysesthesia : a cross-sectional study", Ann Rehabil Med, 41, pp.1028~1038 (2017)
- Burgess J, "Early detection of diabetic peripheral neuropathy : a focus on small nerve fibres", Diagnostics(Basel), 11, pp.165~ (2021)
- Bansevicius D, "EMG activity and pain development in fibromyalgia patients exposed to mental stress of long duration", Scand J Rheumatol, 30, pp.92~98 (2001)
- Ersoz M, "Nerve conduction tests in patients with fibromyalgia : comparison with normal controls", Rheumatol Int, 23, pp.166~170 (2003)
- Wolfe F, "2016 Revisions to the 2010", 2011 fibromyalgia diagnostic criteria, 2016, pp.46, 319~329
- Herdman M, "Development and preliminary testing of the new five-level version of EQ-5D(EQ-5D-5L)", Qual Life Res, 20, pp.1727~1736 (2011)
- Bril V, "Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy", Diabetes Care, 25, pp.2048~2052 (2002)
- Burckhardt CS, "The fibromyalgia impact questionnaire : development and validation", J Rheumatol, 18, pp.728~733 (1991)
- Feldman EL, "Diabetic neuropathy", Nat Rev Dis Primers, 5, pp.41~ (2019)
- Dumolard A, "Central sensitization and small-fiber neuropathy are associated in patients with fibromyalgia", Clin J Pain, 39, pp.8~14 (2023)
- Oh J, "Clinical spectrum and diagnosis of diabetic neuropathies", Korean J Intern Med, 35, pp.1059~1069 (2020)
- Bair MJ, "Fibromyalgia", Ann Intern Med, 172, pp.ITC33~ITC48 (2020)
- Kang JH, "Disentangling diagnosis and management of fibromyalgia", J Rheum Dis, 29, pp.4~13 (2022)
- Nijs J, "Central sensitisation in chronic pain conditions : latest discoveries and their potential for precision medicine", Lancet Rheumatol, 3, pp.e383~e392 (2021)
- Walitt B, "Selective serotonin reuptake inhibitors for fibromyalgia syndrome", Cochrane Database Syst Rev, 2015, pp.CD011735~ (2015)
- Häuser W, "Serotonin and noradrenaline reuptake inhibitors(SNRIs)for fibromyalgia syndrome", Cochrane Database Syst Rev, (1), pp.CD010292~ (2013)
- Pál E, "Small fiber neuropathy : clinicopathological correlations", Behav Neurol, 2020, pp.8796519~ (2020)
- Hovaguimian A, "Diagnosis and treatment of pain in small-fiber neuropathy", Curr Pain Headache Rep, 15, pp.193~200 (2011)
- Porubcin MG, "Diagnostic accuracy of electrochemical skin conductance in the detection of sudomotor fiber loss", Front Neurol, 11, pp.273~ (2020)
- Novak P, "Electrochemical skin conductance correlates with skin nerve fiber density", Front Aging Neurosci, 8, pp.199~ (2016)
- Cascio MA, "Small fiber neuropathy" (2022), StatPearls
- Vecchio M, "A systematic review of pharmacologic and rehabilitative treatment of small fiber neuropathies", Diagnostics(Basel), 10, pp.1022~ (2020)
- Cheng CW, "Fibromyalgia : is it a neuropathic pain?", Pain Manag, 8, pp.377~388 (2018)
- Latremoliere A, "Central sensitization : a generator of pain hypersensitivity by central neural plasticity", J Pain, 10, pp.895~926 (2009)
- Seybold VS, "The role of peptides in central sensitization", Handb Exp Pharmacol, (194), pp.451~491 (2009)
- Chang CT, "Ion channels involved in substance P-mediated nociception and antinociception", Int J Mol Sci, 20, pp.1596~ (2019)
- Paredes S, "An association of serotonin with pain disorders and its modulation by estrogens", Int J Mol Sci, 20, pp.5729~ (2019)
- Stratz T, "Influence of tropisetron on the serum substance P levels in fibromyalgia patients", Scand J Rheumatol Suppl, 119, pp.41~43 (2004)
- Al-Nimer MSM, "Serum levels of serotonin as a biomarker of newly diagnosed fibromyalgia in women : its relation to the platelet indices", J Res Med Sci, 23, pp.71~ (2018)
- Platten M, "Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond", Nat Rev Drug Discov, 18, pp.379~401 (2019)
- Kim H, "Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression", J Clin Invest, 122, pp.2940~2954 (2012)
- Wang Y, "PCC0208009, an indirect IDO1inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala", Biochem Pharmacol, 177, pp.113926~ (2020)